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Abstract
The evolution of colorectal cancer suggests the involvement of many genes. We performed
insertional mutagenesis with the Sleeping Beauty (SB) transposon system in mice carrying
germline or somatic Apc mutation. Analysis of common insertion sites (CISs) isolated from 446
tumors revealed many hundreds of candidate cancer drivers. Comparison to human datasets
suggested that 234 CIS genes are also deregulated in human colorectal cancers. 183 CIS genes are
candidate Wnt targets, and 20 are shown to be novel modifiers of canonical Wnt signaling. We
also identified gene mutations associated with a subset of tumors containing an expanded number
of Paneth cells, a hallmark of deregulated Wnt signaling, and genes associated with more severe
dysplasia included members of the FGF signaling cascade. Some 70 genes showed pairwise co-
occurrence clustering into 38 sub-networks that may regulate tumor development.
It is estimated that on average 7-15 somatic mutations are required for a normal human cell
to undergo malignant transformation1-3. Colorectal cancer progression appears to have an
extended clinical course, with mutation of genes including APC, K-RAS, TP53 and
SMAD4, being frequent events, whilst genomic analysis has implicated many more genes in
the pathogenesis of this disease4-6. The diversity of the mutagenic processes that create
tumors in humans results in many different types of lesions in the cancer genome such that
discriminating cancer driver genes from passengers is often not possible using genome
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analysis alone7. Recently the Sleeping Beauty (SB) DNA transposon system has been used
to identify genes involved in the development of intestinal tumorigenesis8. Insertional
mutagenesis provides the advantage of using engineered elements to initiate mutagenesis
largely through the loss or gain of gene function, while tagging potential cancer genes9. In
the intestine, loss of APC function is widely believed to be an initiating event in the
formation of colorectal cancer, with 80% of sporadic tumors having an APC mutation, while
germline APC mutations are associated with a predisposition to familial polyposis 4,6,10.
APC normally functions to sequester and target β-catenin for degradation through
phosphorylation by GSK-3β. In the absence of APC, β-catenin can freely translocate to the
nucleus where it signals an intracellular cascade impacting upon the transcription of
hundreds of genes6. Here, in mice with somatic or germline mutation of Apc, we performed
large-scale insertional mutagenesis using the Sleeping Beauty transposon system to create a
comprehensive catalog of new candidate drivers of intestinal tumorigenesis 8,9,11-17. Several
hundred candidate driver genes are implicated, allowing novel genetic interactions between
genes and conserved pathways to be explored.
RESULTS
Generation of Mice and Histological Analysis
A cohort of 67 transgenic animals (AhCre;Apcfloxed/wt;Rosa26Lox66SBLox71;T2Onc)
underwent concomitant somatic heterozygous loss of Apc and activation of SB transposase
following Cre induction. Thirty-seven control mice were Apc deficient but unable to
mobilize the transposons (AhCre;Apcfloxed/wt;T2Onc or
AhCre;Apcfloxed/wt;Rosa26Lox66SBLox71) (Supplementary Fig. 1-2). All Apcfloxed/wt mice
eventually developed intestinal tumors, but those with mobilized transposons showed a
significantly earlier onset of disease compared to controls (Fig. 1). Tumors mostly occurred
in the small intestine, with the occasional lesion found in the caecum and colon (Fig. 1c). In
ApcMin mice the experimental group [ApcMin;RosaSBase;T2Onc (10 mice)] developed
disease approximately 30 days earlier than control ApcMin littermates, and had a higher
proportion of colonic lesions (Fig. 1b,d).
A total of 446 tumors (of which 367 underwent histopathological review) were excised for
analysis of transposon insertion sites from the experimental groups; 391 and 55 from the
somatic Apcfloxed and germline ApcMin models, respectively. In addition, 106 (46 somatic,
60 germline) tumors from animals without mobilized transposon were taken for
histopathological review. Tumors were larger and more numerous in Apcfloxed animals with
mobilized transposons (Fig. 1c). The majority of tumors were oligocryptal and tubulovillous
adenomas (Supplementary Table 1). However, a proportion of tumors from the somatic
model with mobilized transposons showed moderate or severe dysplasia (n=40, 23 mice),
while 10 showed evidence of invasion (9 mice) (Fig. 1e-g). Both somatic and germline
models produced microsatellite stable tumors (Supplementary Fig. 3).
Identification of Sleeping Beauty Common Insertion Sites (CISs)
In total, 146,249 non-redundant transposon insertion sites (an average of 328 per tumor)
were identified after 454 sequencing and mapping to the mouse genome. We employed two
statistical frameworks to determine common insertion sites (CISs): Monte Carlo (MC)
simulations, and a Gaussian kernel convolution (GKC) algorithm that was optimized to take
into account the TA bias of the Sleeping Beauty transposon8,18,19. To maximize statistical
power, we pooled insertions from both the Apcfloxed and ApcMin models. The concordance
between the two statistical methods was 60%, based on overlapping CIS regions; Monte
Carlo analysis identified 749 CISs, while GKC analysis with 30 Kb and 120 Kb kernel sizes
identified 919 and 641 CISs, respectively, equating to 997 unique CIS regions (867 genes)
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(Supplementary Tables 2a-d). The results of the GKC analysis were used to define a
discovery set for downstream analyses and refinement by comparison to other datasets.
Importantly the T2Onc transposon can generate gain-of-function mutations by integrating in
or near genes and driving over-expression from the MSCV promoter in the transposon, and
also loss-of-function mutations by integrating in genes and hijacking transcription by use of
splice acceptors and polyA signals in the transposon. Insertions may also generate
neomorphic alleles, or potentially disrupt regulatory elements around cancer gene loci. To
identify CISs that may be the result of preferential insertion hotspots, we mobilized
transposons as described above and collected a total of 48 tissue samples for insertion site
analysis 2 weeks and 10 months after mobilization. Sequencing of the insertions from these
tissues yielded 17,358 unique insertions and 35 CISs using GKC analysis. Only 1.8% of
CISs called from the tumors overlapped with these control CISs (Supplementary Table 2e).
Analysis of CISs associated with known cancer genes allowed us to establish a set of rules
that were used to assign insertions to genes. These rules are outlined in the supplementary
methods (Supplementary Fig. 4-9, Supplementary Tables 3-4).
Tumor Etiology
The implication that there is positive selection for hundreds of candidate cancer genes
following insertional mutagenesis initially appeared surprising. Consideration of the tumor
etiology is important in understanding this observation. First, we determined that multiple
tumors obtained from individual mice were biologically independent because their insertions
were no more likely to be in the same genomic locations as tumors from different mice
(Supplementary Fig. 10). Therefore, separate lesions taken from the same mouse intestine
evolve independently. Second, consideration of Apc (mutated in 91.3% of tumours)
demonstrates not only that mutation of the second allele is a near obligate event in this
model, but also that it is recurrently mutated (65% of tumors had 3 or more insertions). This
must arise from selection for serial truncating mutations within Apc during tumor
development, as has been shown for the attenuated form of FAP – the ‘three hit’
hypothesis20. This observation also suggests tumor oligoclonality, supported by the number
of non-redundant insertions per tumor being 10-fold greater than the number of transposons
available for mobilization (328 versus 30). A corollary is that transposons are inefficiently
mobilized following Cre induction. This was confirmed by measuring the copy number of
transposons retained at the donor locus: around 40% of the original 30 copies of T2Onc are
retained (n=24, mean number of unmobilized transposons = 11.19 copies, SD = 2.611)
(Supplementary Methods). Since 50% survival is reached at around 16 weeks post-induction
(Fig 1a), the rate of insertional mutagenesis is less than 1 event/cell/week (the presence of
contaminating stromal cells in which the transposase is not activated may mean that this rate
is an underestimate). Thus, transposon mobilization is inefficient and ongoing throughout
tumorigenesis, with the extensive accumulated mutational burden arising from selective
forces. This leads to the development of oligoclonal tumours, and explains in part the
number of insertions we identify. As a consequence many mutated genes make a relatively
small contribution to tumor growth.
Overall, the average number of insertions per tumor that contributed to a CIS was 1.14,
demonstrating that some tumors contained multiple insertions contributing to a CIS
(Supplementary Tables 5a-d). For example, 5.4% of tumors had 2 or more insertions in
Ctnnd1, 4.7% of tumors had 2 or more insertions in Kcnq1, and 4.0% of tumors had 2 or
more insertions in Lass6. This may be due to the presence of multiple independent tumor
sub-clones within the tumor bulk, suggesting that the mutation of these genes may represent
a bottleneck in tumor evolution whereby individual cells within the tumor acquire different
mutations in order to progress. This observation is also consistent with these genes
functioning as tumor suppressors, requiring biallelic mutations before they become operative
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in cancer development21. Given the above, we cannot distinguish between these
possibilities.
Other frequently mutated CIS genes previously implicated in intestinal cancer include Pten,
Smad4 and Bmpr1a, which were mutated in a significant number of tumors (13.2%, 15.7%
and 7.6% respectively (P<1.51 × 10−5)) demonstrating that transposons mutate the same
genes that are disrupted in the human disease. In 48 tumors with single insertions in Pten,
Smad4 and Bmpr1a we sequenced the coding regions of these genes and found no further
spontaneous mutations, indicating that the insertions in these genes may be acting in a
haploinsufficient manner (data not shown).
Transposons Drive Intestinal Tumorigenesis via Conserved Pathways
To evaluate the types of genes involved, and to facilitate the filtering of the discovery set of
CIS genes, we used Ingenuity Pathway Analysis (IPA) (Ingenuity Systems Inc.). We
determined that the CISs in this screen were significantly enriched in cancer-associated
signaling pathways, accounting for 113 CIS genes. For example genes in the PI3K/Akt,
ERK/MAPK, Wnt and integrin signaling pathways were mutated with P-values of 2.69 ×
10−8, 2.76 × 10−8, 2.13 × 10−7 and 1.39 × 10−7, respectively (Supplementary Table 6). Loss
of function mutations, characterized by intragenic transposon insertions in both orientations,
appeared to predominate. Insertions near K-Ras, mutated in around 40% of sporadic human
colorectal carcinomas, were present in only 5% of tumors22,23. In addition, mutations in p53
and Smad4 were found at a frequency of only 5.2% and 15.7%, respectively. To assess the
ability of our insertional mutagenesis screen to exploit the K-Ras, p53 and TGFβ signaling
pathways, we examined insertions in CISs associated with genes immediately up or
downstream of these key cancer genes in each signaling cascade, and determined that they
are frequently mutated (all with P ≤2.23 × 10−5) (Fig. 2). In total, 38.6% of tumors carried
mutations in genes in the K-Ras pathway, 48.0% in the TGFβ pathway, and 61.4% in the
p53 pathway. Just under half of all tumors carried mutations in CISs associated with genes
in more than one of these pathways, with 15.9% carrying mutations in all three (Fig. 2).
Consideration of tumor pathology with the number or type of pathways mutated showed no
correlation with more dysplastic disease (data not shown). However, a proportion of CIS
genes were over-represented in tumors carrying insertions in these pathways; around 40, 43
and 36 CIS genes for the K-Ras, p53 and TGFβ signaling pathways, respectively
(Supplementary Tables 7-9). Therefore, transposon insertions drive tumorigenesis using the
same conserved pathways as are operative in human cancers, and these are associated with
additional gene insertions.
Cross-Species Comparison
Human cancer genomes acquire mutations that not only drive tumorigenesis, but that also
reflect the signatures of the mutagenic processes that have driven their evolution7. Using
cross-species oncogenomics, we compared the CISs identified in this study to human
colorectal cancer datasets to implicate up to 234 CIS genes in the human disease (Fig. 3a-d,
Supplementary Table 10-14). Genes overlapping in two or more of the datasets (34 genes)
were distributed throughout the CIS list and include important known CRC genes such as
Fbxw7, K-Ras and Ctnndb1 (Fig. 3e, Supplementary Tables 15-16). In addition to
comparisons with human tumor studies, we also identified 55/77 of the CIS genes identified
in a recent SB transposon screen in the intestine, but by using a significantly larger number
of tumors (446 versus 135) and deeper sequencing, we extend this CIS list by 12-fold
(Supplementary Table 17)8. The 55 CISs identified by Starr et al.8, were distributed
throughout our entire CIS list (Supplementary Table 18), with 7 identified in the top 20
genes of the 30 Kb and 120 Kb GKC analyses (Supplemental Figure 11, Supplementary
Table 19). Interestingly, an additional 10 proteins encoded by CIS genes overlap with over-
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expressed proteins and transcripts identified in a screen of adenomas from ApcMin mice,
including Cul1 and Pdlim124,25. Furthermore, recent studies using intercrosses with
ApcMin/+ mice have shown that Pparg, Pten, Rb1, Mapk1, Stat3, Ephb4, Myb, Cd44 and
Smad3 co-operate with Apc loss in intestinal tumorigenesis, all of which were detected in
our analysis26-34. Finally, comparison of our data with a CGH dataset from spontaneously
evolving tumors from ApcMin mice showed a significant overlap of CIS genes with regions
rearranged in these tumors (P = 6.75 × 10−7) (Supplementary Methods)35, suggesting that
transposons identify the same genes that are disrupted in spontaneous cancers. Importantly,
224 genes were predicted to be disrupted in each of these spontaneous mouse tumors, a
number 3-fold higher than the average number of CISs per tumor (76).
Association of CIS with the Wnt Pathway
The observation that there was enrichment for subsets of CIS genes in tumors with
mutations affecting the p53, K-Ras and Wnt pathways suggested that one explanation for so
many potential cancer drivers is their modulation of known cancer pathways. To test this
functionally, we explored one such pathway, namely the Wnt signaling pathway. The
presence of TCF/β-catenin consensus binding sites in promoter regions of 183 CIS genes
suggested that they are potential Wnt targets (P = 1.1×10−64) (TRANSFAC 2009.3,
BIOBASE GmBH)36. Of these, 37 genes showed significant copy number changes in a
CGH analysis of human colorectal cancers (Fig. 3; Supplementary Table 20), and were
assessed to determine if they were potential modulators of Wnt signaling. The CellSensor
Wnt reporter system in SW480 colorectal carcinoma cells was used in conjunction with
siRNA knockdown, and revealed 16 genes as being negative regulators of Wnt signaling,
and 4 genes as positive regulators (Fig. 4). To control for off-target effects, 9 randomly
selected siRNAs were tested and were found to have no effect on Wnt reporter activity
(Supplemental Fig. 12). Overall this represents a significant enrichment for genes that
regulate canonical Wnt signaling in our screen (P<0.005, Fisher’s exact test)
(Supplementary Methods). The E3 ubiquitin-protein ligase NEDD4, known to
polyubiquinate the tumor suppressor PTEN, appears to negatively regulate Wnt signaling,
suggesting a potential link between two distinct tumor suppressor mechanisms involving
APC and PTEN. Rcor1, Onecut2 and Zfpm1 are transcription factors, knockdown of which
caused a robust increase in Wnt signaling, thus confirming a regulatory role for these genes
in the Wnt pathway.
A subset of human colorectal cancers containing an increased proportion of Paneth cells has
been described previously 37. In the present study a significant number of tumors (83/367)
contained an enlarged proportion of these cells (Fig. 1h). Mouse models in which germline
Apc mutations are engineered to retain a single domain of β-catenin binding/degradation
and thereby retain some residual functionality from the truncated allele (1322T mutation)
have also been shown to carry tumors with a higher proportion of Paneth cells and a more
dysplastic phenotype 38. Thirty-six CISs were identified as being over-represented in this
group when compared to non-Paneth cell tumors (Table 1). Of these, eight have previously
been identified as Wnt targets36. Interestingly Eps8, which we show to be a positive
regulator of the Wnt pathway (Fig. 4), is also a CIS gene enriched in the Paneth cell-
containing tumors. Three of the 36 genes (Usp10, Eps8 and Cask) have been shown to be
upregulated in intestines showing an increase in Paneth cell number due to deletion of
Klf939. These results further suggest an important role in the fine-tuning of Wnt signaling
throughout tumor development, with one outcome being altered tumor pathology.
We also compared tumors histopathologically classified as presenting with either mild or
moderate atypia (n=332) against those with moderate dysplasia and severe dysplasia (n=35);
23 genes were over-represented in the tumors with a more severe phenotype suggesting that
these genes contribute to disease progression (Table 2). Importantly, genes involved in FGF
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signaling (Frs2 and Grb2) feature; it has been proposed that co-activation of this pathway
with Wnt signaling results in a more malignant phenotype40. From this list Uhrf2 has been
associated with an increased risk of colon cancer41, while a gene fusion of Tmprss2
(Tmprss2-Erg1) has been linked with a poor prognosis in prostate cancer42. Slk is a serine-
threonine protein kinase, which, when complexed with Asap1, promotes CRC metastasis43.
Therefore, these over-represented genes may provide new insights into CRC progression.
Co-occurrence of Genes
Co-occurring CISs (co-CISs), where two CISs were co-mutated at a higher frequency than
expected by chance, were identified. As expected the majority of co-CISs we identified were
with Apc, since mutation of the wild type allele of Apc is a near obligate event in
adenomagenesis in our model. We focused on other co-CIS identifying 70 CIS genes
involved in statistically significant pairwise co-occurrences constituting 38 networks, the
largest containing 28 genes (Supplementary Table 21, Fig. 5). Several of the interactions
identified were with CISs associated with known tumor suppressor genes, such as Lrrc41
with Pten, and Lamp1 with Smad4 (or Mex3c) (Fig. 4). Analysis of human CGH data
provided independent support for two of the co-CISs: those between Mex3c/Smad4 and
Lamp1 and between Sfi1 and Adnp (Supplementary Table 20)44. At the centre of the largest
network we found the CIS Atp6v0a2/Tctn2; Tctn2 has previously been shown to be a gene
mutated in both mouse and human colorectal cancers35. Intriguingly, these networks include
genes that co-occur with well-established cancer drivers such as Pten, Smad4 and Rac1.
DISCUSSION
We have performed an extensive forward genetic screen in the intestinal tract using mouse
models of somatic and germline neoplasia. These studies reveal hundreds of genes in
addition to 38 genetic networks between these genes that are candidate drivers of
carcinogenesis. The value of this discovery set will ultimately be established by the
overlaying of high-throughput mutation data from human colon cancers. However, it is
worth noting that our screen identified novel genes recently found to be mutated in human
colorectal cancers including, MLL3 and CDK844,45. In line with previous commentaries that
implicate selection pressures and not elevated mutation rates in driving tumorigenesis, we
confirm that the Sleeping Beauty transposon is inefficiently mobilized, generating a very
low rate of cellular mutagenesis46. The high number of accumulated mutations observed is
thus a consequence of selection acting on increasingly diverse populations to create highly
oligoclonal tumours.
Using cross-species oncogenomics, we can independently implicate around a third of our
CIS genes in colorectal neoplasia from human studies. Functionally, we identify 20 novel
regulators of Wnt signaling that implicates these genes in colorectal tumorigenesis through
this pathway. Collectively, our analysis provides a rich catalogue of candidate genes that
represent potential diagnostic, prognostic and therapeutic targets, and defines the breadth of
genes that may contribute to cancer of the intestine. Our screen is in agreement with a
previous exome re-sequencing study of human colorectal cancers, which predicted many
hundreds of functional mutations in human cancer47.
The number of genes identified in our screen suggests that many more genes than previously
thought can contribute to colorectal cancer development if appropriately altered. Others
have suggested that around 10 genes in any one cancer may drive cancer development, with
each cancer carrying common driver mutations and also rarer mutations that may also
contribute to cancer growth1-3,7. Determining which genes are drivers is complicated by a
lack of knowledge of the functional significance of the many hundreds of infrequent somatic
alterations that are acquired during cancer development, and because at present no study has
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systematically analyzed the landscape of somatic mutations in a human cancer type in a
large number of samples at base-pair resolution. In this screen, we use a transposon that
must integrate proximally to a gene to function, and in this way loci-containing candidate
cancer genes were identified when they were mutated at a frequency higher than expected
by chance.
While genes that are infrequently mutated in human cancer and in our screen are less likely
to be major players in tumorigenesis, population theory suggests that any genetic alteration
that causes a fractional increase in the ability of a cell to outgrow other cells may contribute
to tumorigenesis48,49. The classical model for this is yeast, in which as many as 6% of
mutations that alter the growth kinetics of a population of cells can result in the outgrowth of
a more vigorous population50. Likewise, in human studies there is evidence to suggest that
mutations that fractionally increase the fitness of a cell within a population can predispose
that cell to evolve into a cancer51. In this way, many of the genes that we have discovered in
this screen may contribute independently or combinatorially to tumor development. This
interpretation of our study is supported by several lines of evidence. First, we have shown
that the majority of cancers in this screen carry mutations in Apc, and furthermore, that 20
genes can modify canonical Wnt signaling, even in tumor cell lines in which Apc is already
disrupted. There is a long standing observation that the second somatic hit identified as
affecting APC in sporadic and familial colorectal cancers is influenced by the nature of the
first mutation, such that at least one β-catenin binding domain is retained in one allele. The
interpretation is that the complete loss of Apc function is not tolerated by the normal
epithelium (the ‘just-right’ phenomenon). Hence, the initial transformation event does not
give ‘maximal’ dysregulation of the pathway 52. Loss of function mutations in SFRPs (Wnt
antagonists) in human colorectal cancers have been found to increase Wnt signaling over
that resulting from the initiating APC mutation 53,54. Moreover, one of the key effects of
both Kras and Braf mutations is to synergize with Apc mutations by enhancing Wnt
signaling 55. In short, it is well established that the dysregulation of Wnt signaling is not a
single event, but is subject to modulation throughout cancer development. Fine-tuning of
Wnt signaling is one likely substrate for achieving fractional increases in fitness.
Second, many of the genes discovered in this screen are associated with known colorectal
cancer pathways, such as the Wnt, PI3K and Ras cascades. Genes associated with these
pathways are significantly enriched for mutations over the level that would be expected by
chance. This suggests that many of the genes recurrently mutated by transposons are
functioning through these pathways to optimize tumor cell growth. Finally, many CIS genes
can be clustered into other novel pathways using pathway analysis tools, suggesting in
addition to the main oncogenic routes other pathways are also operative in bowel cancer,
and that if appropriately altered can contribute to tumorigenesis. Follow-up functional
analysis will help us gain a better understanding of how the CIS genes we have discovered
contribute to CRC.
The co-occurring networks of mutated genes discovered from this screen suggest that the
mutation of many genes is important in colorectal cancer development. The presence of co-
mutated genes in a cancer does not however necessarily mean that mutations of these genes
function in a cell autonomous manner to promote cancer growth. Each of the tumors we
analyzed is composed of multiple tumor cell clones, and this heterogeneity may favor
cellular interactions that result in some of the co-occurrences we observe.
In conclusion, we have demonstrated that insertional mutagenesis in the mouse, performed
on a hitherto unprecedented scale, reveals hundreds of candidate cancer driver genes that
promote colorectal cancer development.
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METHODS
Generation of mice
All experiments were performed on a C57BL/6J background. ApcMin mice: ApcMin mice
have been described previously56. Apcfloxed/wt mice: To model sporadic cancer formation
we used Ah-Cre/Apcfloxed/wt mice in which the first initiating event (loss of exon 14 of Apc
and a concomitant frameshift mutation in exon 15 is induced somatically following
administration of β-naphthoflavone (bNF)17. In Ah-Cre mice the CYP1A1 promoter drives
expression of Cre throughout the intestinal tract57. T2Onc mice: We used the mouse line
LC76 with a transposon donor locus located on chromosome 19. RosaSBase mice: These
mice have been described previously12. Conditional Sleeping Beauty transposase mice
(Rosa26Lox66SBLox71): The conditional Sleeping Beauty transposase allele was generated
by cloning the HSB5 variant of the Sleeping Beauty transposase in the antisense orientation
between Lox66 and Lox71 sites. This cassette was targeted to the Rosa locus in E14Tg2a ES
cells, transmitted onto a C57BL/6J background and then backcrossed to C57BL/6J.
Expression of Cre in these mice catalyzes recombination between the Lox66 and Lox71 sites
inverting the transposase cDNA so it can be expressed from the CAGGS promoter. The
CAGGS promoter was used in the transposase allele because it drives reproducible
expression in a broad range of cells and tissues. Ah-Cre(hom)/T2Onc(het) mice were
maintained by crosses to Ah-cre(hom). Rosa26Lox66SBLox71/Apcfloxed/floxed mice were
maintained as obligate homozygotes for both alleles. Experimental and control cohorts were
obtained in a single generation by crossing Ah-Cre(hom)/T2Onc(het) mice to
Rosa26Lox66SBLox71/Apcflox which gave obligate inheritance of Ah-Cre,
Rosa26Lox66SBLox71, Apcfloxed alleles and segregation of the T2Onc allele.
For the germline model ApcMin mice were intercrossed with Rosa26SBase mice, which
express the SB transposase ubiquitously, and offspring from this cross were in turn mated to
T2Onc mice to obtain experimental and control cohorts.
Tumor Watch Analysis
Animals aged between 6-11 weeks received intraperitoneal injections of 80mg/kg β-
naphthoflavone daily for 5 days. Experimental mice were monitored on ‘tumor watch’ and
sacrificed when moribund. Normal and tumor tissue was collected from each mouse and
samples were divided into two parts; one section was snap frozen in liquid nitrogen for
splinkerette PCR, while the other section was stored in 10% NBF, transferred to 70% EtOH
and processed for histopathological analysis. All animal procedures were approved by the
UK Home Office.
Splinkerette PCR
Genomic DNA was extracted from snap frozen tumor samples using Gentra Puregene kits
(Qiagen). Splinkerette PCRs were performed as previously described19.
Generation and Pre-processing of 454 Reads
Pools of transposon-genome junction PCRs from the 446 tumor samples were sequenced on
the “454 FLX” platform generating a total of 1,763,374 DNA sequence reads. The raw reads
were processed removing SB transposon sequence, DNA barcode tags, and sequence beyond
the restriction enzyme site. Processed sequences shorter than 20 nucleotides were discarded
from the subsequent genome mapping process since they have an increased tendency to map
to multiple genomic locations. Following this filtering process 1,316,365 clipped sequences
remained for alignment to the mouse genome.
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Mapping Clipped Sequences to the Mouse Genome and Identifying Insertion Sites
The set of clipped sequences were mapped to the mouse genome (NCBI Build 37 assembly)
using the ssaha2 alignment algorithm (version 2.5)58. Of the 1,316,365 clipped sequences
aligned using ssaha, 898,082 unique alignments were reported (50.93% of the original
reads). All aligned sequences were checked to confirm that the two nucleotides adjacent to
the start of each alignment were TA. Aligned sequences from the same tumor, that were
generated using the same restriction enzyme and that mapped to the same genomic location,
were merged together to report a single insertion site. Chromosome 1 contains the donor site
of the T2Onc transposon and insertion site reads mapping to this chromosome were removed
to negate CIS calls resulting from “local hopping”. Further, insertions were filtered from the
loci of the genes En2 (chr5:28492236-28498706) and Foxf2 (chr13:31717648-31723271) as
elements from these loci are found in the T2Onc transposon. These filtering steps resulted in
146,249 insertion sites which were used for CIS analysis (Supplementary Materials Table
S2a).
Identification of Common Insertion Sites
Common insertions sites (CISs) were identified using two complementary approaches:
(1) Gaussian Kernel Convolution: CIMPLR—The Common Insertion Mapping
Platform (CIMPLR) is a Gaussian kernel convolution (GKC) method developed in a
previous study to identify CISs in retroviral insertional mutagenesis screens18. An enhanced
version of the method was developed for SB screens which considers the local density of TA
sites within the genome. Kernel widths of 30 Kb and 120 Kb nucleotides were selected for
CIS detection.
For each CIS, the genomic location of its kernel peak was used as the reference point to
assign gene annotations. A CIS peak was associated with a gene if either it lay within the
coding region of a gene or was within +/− 150 Kb nucleotides of its nearest gene. If the
distance to the nearest gene was greater than 150 Kb nucleotides, no gene name was
assigned. Using 30 Kb and 120 Kb kernels 919 and 641 CISs were reported, respectively
(Supplementary Materials Tables S2a,b).
To summarise the CIS predictions from the two independent kernel widths, a method of
combining predictions across the kernels was devised, such that where CISs from the two
kernels overlapped, those CISs with the smallest “footprints” on the genome were reported.
Using this procedure, a total of 997 cross-scale CISs were predicted (Supplementary
Materials Table S2c). Depending on the size and location of CISs, genes may be associated
with multiple CISs. Consequently the 997 cross-scales CISs are associated with 867 unique
genes.
(2) Monte Carlo Simulations—In a previous study Starr et al. developed a Monte Carlo
(MC) simulation method to identify CISs in a colorectal cancer screen8. This method
determines the local density of insertions in a given window that exceed the expectation of
observing this density by chance. The 146,429 insertions were analysed using a Perl script
that implemented the Starr et al. MC method (personal communication: Kevin A.T.
Silverstein, Univ of Minnesota). Five independent simulations were performed of 100
iterations each. The range of insertions to be detected in a CIS varied from 5 to 20, and the
size of windows examined in the simulations ranged from 10 Kb to 150 Kb, in increments of
1 Kb.
March et al. Page 9
Nat Genet. Author manuscript; available in PMC 2012 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Using a similar approach for gene annotation as in the CIMPLR method, described above,
CISs were annotated according to the nearest mouse gene. A total of 749 CISs were reported
by the MC simulation method.
Discovery Set vs Genome-wide adjusted CISs—The analysis described in our paper
used a discovery set of CIS calls that were compared to other datasets to help filter
passengers from drivers and to identify other collections of genes of biological interest. This
approach (described above) identified statistically significant CISs on a chromosome-by-
chromosome basis, and was motivated by the observation that there were significant
differences in the number of insertions, and hence CISs, per chromosome. In Supplementary
Table 2c we also present a set of CISs calculated using genome-wide GKC with more
stringent genome-wide cut-offs.
Co-occurrence
Pairwise comparisons were made between the 997 combined CISs from the GKC analyses,
recording counts for all 446 tumor samples for the following cases: shared insertions
between the two CISs, insertions unique to each CIS and samples that had no insertions in
either CIS (Fig. 5). Where tumor samples had multiple insertions within a CIS, a single
occurrence was recorded. The counts were converted into contingency tables and Fisher
Exact Tests were performed. To account for multiple testing on the 496,506 comparisons, a
q value was generated for each test. CIS pairwise comparisons with adjusted p-values of P <
0.05 were used to construct the resultant co-occurrence networks.
Software
Cytoscape software (version 2.7.0, www.cytoscape.org) was used to create the CIS
interaction network.
Cell Culture
CellSensor LEF/TCF-bla SW480 cell line (Invitrogen - further details included in
Supplementary Methods) was cultured in RPMI medium 1640 with GlutaMAX (Invitrogen)
supplemented with dialyzed FBS (Invitrogen), non-essential amino acids (Invitrogen),
sodium pyruvate (Invitrogen), blasticidin (Invitrogen) and penicillin/streptomycin
(Invitrogen) in a 37 °C, 5% CO2 incubator.
CellSensor Experiments
CellSensor LEF/TCF-bla SW480 cells (Invitrogen) were seeded at 2.5 × 105 cells in 96-well
plates and transfected with 240nm siRNA (Dharmacon) or medium GC RNAi oligo negative
control duplex (GC control) (Invitrogen) or AllStars Neg. Control siRNA (siNT control)
(Qiagen) for a final concentration of 20 nm, using Lipofectamine RNAimax (Invitrogen).
After 48 h cells were treated with Liveblazer FRET B/G loading kit (Invitrogen), incubated
for 2 h at RT and read on a spectrophotometer (Tecan) at an excitation wavelength of 409
nm and emission wavelengths of 460 nm and 530 nm. Emission ratios were calculated from
these values. Experiments were carried out in triplicate on three separate occasions and data
were statistically analysed using a Student’s t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. SB transposon mobilization increases morbidity and tumor burden of Apc-deficient
mice
(a) Kaplan-Meier survival curve comparing Apcfloxed experimental (Ah-Cre/Apcfloxed/wt/
Rosa26Lox66SBLox71/T2Onc) (black line) and control mice (Ah-Cre/Apcfloxed/wt/T2Onc and
Ah-Cre/Apcfloxed/wt/Rosa26Lox66SBLox71) (grey line) (log-rank P<0.001). (b) Kaplan-Meier
survival curve comparing ApcMin experimental (ApcMin/RosaSBase/T2Onc) (black line),
ApcMin control mice (ApcMin/RosaSBase and ApcMin/T2Onc) (grey line) and RosaSBase/
T2Onc control mice (green line) (log-rank P<0.0057). (c) Average polyp size and number in
Apcfloxed experimental mice (n=3), and matched littermate Apcfloxed control mice (n=3) at
18 weeks post-induction. All polyps visible under the dissecting microscope at 6x
magnification were counted and grouped into those that were non-excisable (black bars)
(<3mm) and those that could be excised for further analysis (>3mm) (grey bars). Average
polyp number for small intestine and caecum/colon is shown. (d) Average number of
excisable polyps (>3mm) from small intestine, caecum and colon of ApcMin experimental
mice (n=10) and ApcMin control mice (n=7) at 10-22 and 17-30 weeks of age respectively.
β-catenin immunohistochemistry (upper panel of each) and hematoxylin and eosin staining
(lower panel of each) of representative tissue from Apcfloxed mice showing (e) a
tubulovillous adenoma at 18 weeks post-induction, (f) an adenoma at 28 weeks post-
induction, (g) an adenoma at 17 weeks post-induction with the arrow indicating the region of
adenocarcinoma in the submucosa. (h) Lysozyme staining of representative tissue from an
Apcfloxed/wt mouse at 22 weeks post-induction, with the arrow indicating Paneth cell
differentiation. All scale bars = 100μm.
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Figure 2. Comparison of Sleeping Beauty insertions in K-Ras, p53 and TGFβ signaling pathways
CIS genes immediately upstream or downstream of K-Ras, p53 or Smad4 were identified
and analyzed for the occurrence of transposon insertions. Percentages of tumors with
insertions in genes are indicated in italics. Percentages in bold show the overall proportion
of tumors with insertions in each pathway.
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Figure 3. Cross-species comparison of CISs with cancer datasets
(a) 47 CIS orthologs of gene products found to be up-regulated or down-regulated in a
proteomic comparison of nuclear matrix fractions from human adenomas and
adenocarcinomas (Supplementary Table 14) 59. (b) 43 CIS orthologs of genes identified
through exon re-sequencing of human colorectal tumors, 13 of which were highlighted as
potential drivers by the authors (P= 0.003) (Supplementary Table 13) 47. (c) 236 CIS
orthologs of genes reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) as
harboring mutations in human sporadic colorectal cancers (36 orthologues in colorectal
cancer) (Supplementary Table 12) 60. (d) 143 CIS orthologs of genes found in deleted or
amplified regions in 123 human sporadic colorectal cancers through CGH analysis (q<25%)
(P = 0.025) (Supplementary Tables 10 & 11) 44. Genes in black indicate CIS orthologs that
overlap in two or more datasets. (e) Distribution of CIS gene orthologs from the 30 Kb
Gaussian Kernel Convolution analysis. Genes are shown in rank order according to the
percentage of tumours containing a given CIS (and then by height of the CIS peak). Some
genes such as Mll3 contain two CIS regions and are therefore shown twice. Genes in bold
indicate well-known CRC genes.
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Figure 4. Identification of novel Wnt targets with tumourigenic potential
Potential regulators of Wnt signaling were identified by analysis with TRANSFAC 2009.3
(BIOBASE GmbH). The results were then cross-referenced with CIS corresponding to
orthologs of genes identified from the CGH analysis of human sporadic colorectal cancers44
to generate a final set of CIS genes for further study. SW480 cells containing a stably
integrated β-lactamase reporter gene under the control of the LEF/TCF binding consensus
sequence were transiently transfected with siRNA (final concentration 20nM) and processed
after 72 h. FRET read-out was measured using the manufacturer’s standard protocol. The
fold change represented in the graph is calculated with respect to GC control. Error bars: s.d,
n=4. Data were pooled from three independent experiments to determine statistical
significance by Student’s t-test (***P<0.001, **P<0.01, *P<0.05).
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Figure 5. Co-occurring CISs can be grouped into interacting networks
CISs generated from the CIMPLR 30 Kb and 120 Kb analyses were merged and pairwise
comparisons between each CIS were performed. Contingency tables were constructed for
each comparison and a Fisher-Exact test was performed. To account for multiple testing a q
value was generated for each test and adjusted P values of P<0.05 were reported. This
generated 70 co-occurring relationships in 38 networks, three of which are shown. CIS are
represented by the nearest associated gene and the thickness of each interconnecting line
between two genes represents the level of significance of the co-occurrence.
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Table 1
Genes over-represented in tumors containing differentiated Paneth cells.
Gene ID Total
insertions
Insertions in
Paneth tumors
Sample specific
P-value
Usp10 13 8 0.001
Tnpo3 25 12 0.002
Slmap 17 9 0.003
Pak2 21 10 0.004
Ppm1b 38 15 0.005
Mbnl1 26 11 0.008
Ncoa4 26 11 0.008
Ppp1r2 48 17 0.009
Tax1bp1 30 12 0.010
CIS7:143946337_30k 14 7 0.012
Bspry 18 8 0.016
Frs2 32 12 0.017
Zfx 12 6 0.019
Sfrs7 26 10 0.023
Spin1 19 8 0.023
Ppp1r12a 93 27 0.024
9130404D08Rik|Gatad2a 41 14 0.024
Fubp3 16 7 0.027
Eps8 38 13 0.029
Fat1 38 13 0.029
Bclaf1|Mtap7 46 15 0.031
Styk1 27 10 0.031
Cask 20 8 0.032
Rps27 20 8 0.032
Ash1l 39 13 0.036
CISX:39487624_30k 24 9 0.036
Nipbl 47 15 0.037
Mlxip 28 10 0.039
CIS9:21215498_30k 21 8 0.043
H2afy 21 8 0.043
Ocln 21 8 0.043
Nacc1 25 9 0.047
Tomm70a 25 9 0.047
Akap9 29 10 0.049
CIS11:50153019_30k 29 10 0.049
Nfib 61 18 0.050
CIS that are not located within ± 150K base pairs of a gene are labeled identified as ‘CIS’ followed by the chromosome, the peak location of the
Gaussian kernel and the kernel size.
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Table 2
Genes over-represented in tumors with severe pathology.
Gene ID Total
insertions
Insertions in
severe tumors1
Sample specific
P-value
Uhrf2 22 14 0.002
Kdelc2 64 49 0.004
Fgfr2|Oat 12 7 0.007
Frs2 28 20 0.010
Msl2 23 16 0.011
Tmed10 18 12 0.012
Fnbp1l 40 30 0.012
Tpm1 24 17 0.014
Atp1a1 37 28 0.020
6430598A04Rik 20 14 0.020
Chn2 15 10 0.021
Grb2 26 19 0.022
Agpat3 38 29 0.023
Tmprss2 38 29 0.023
Chd6 39 30 0.027
C77080 11 7 0.028
Cnot2 53 42 0.033
Brwd1 28 21 0.033
Rtn4rl1 28 21 0.033
Tnrc6c 23 17 0.038
Bspry 18 13 0.045
CIS12:88752362_30k 30 23 0.046
Slk 30 23 0.046
1
Tumors showing severe atypia, moderate dysplasia or severe dysplasia
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